Org 50081 + Org 50081 + Placebo + zopiclone

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sleep Initiation and Maintenance Disorders

Conditions

Sleep Initiation and Maintenance Disorders, Mental Disorders

Trial Timeline

Oct 1, 2007 → Sep 1, 2008

About Org 50081 + Org 50081 + Placebo + zopiclone

Org 50081 + Org 50081 + Placebo + zopiclone is a phase 1 stage product being developed by Merck for Sleep Initiation and Maintenance Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00798395. Target conditions include Sleep Initiation and Maintenance Disorders, Mental Disorders.

What happened to similar drugs?

20 of 20 similar drugs in Sleep Initiation and Maintenance Disorders were approved

Approved (20) Terminated (2) Active (0)
Zolpidem MR + EstazolamAstellas PharmaApproved
Zolpidem MR + Zolpidem IRAstellas PharmaApproved
Lemborexant + PlaceboEisaiApproved
Eszopiclone + Placebo controlSumitomo PharmaApproved
Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved
Lunesta + Placebo controlSumitomo PharmaApproved
LunestaSumitomo PharmaApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00798395Phase 1Completed

Competing Products

20 competing products in Sleep Initiation and Maintenance Disorders

See all competitors